Merck & Co. Stock - weekly review and pharma peer comparison
19.06.2026 - 21:36:14 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 19:30 UTC. Details in the imprint.
Merck & Co. (US58933Y1055) remains one of the larger names in global pharmaceuticals by market value. The stock ends this week in a steady trading range while investors reassess big pharma after recent moves across the sector.
All news and data on Merck & Co. stock
Stay on top of Merck & Co. with bundled headlines, key figures and regulatory filings for the New York-listed pharma heavyweight.
How Merck stock ended the week
Merck & Co. shares last closed at $114.04 on the New York Stock Exchange on 06/18/2026, with after-hours trading indicating a small uptick to $114.07 later that evening, according to MarketBeat data. MarketBeat quote overview
This puts Merck’s equity value at roughly $281.65 billion, positioning the company firmly in the global large-cap pharma bracket alongside US and European peers. MarketBeat key stats
Weekly review and sector comparison
Over the past 30 days, MRK stock is up around 0.9%, reflecting a modest gain compared with more volatile swings seen in some biotech names over the same period. TrendSpider technical snapshot
Merck trades at about 32 times trailing earnings, with a dividend yield close to 3%, a profile that investors often compare with other diversified pharma groups such as Pfizer, Bristol Myers Squibb and Johnson & Johnson. MarketBeat valuation data
What drives Merck’s earnings power
Merck & Co. generates most of its revenue from human pharmaceuticals, led by its cancer therapy Keytruda, which delivered about $8.0 billion in sales in the first quarter of 2026, according to a recent Zacks summary of the company’s performance. Zacks research note on Merck
Beyond oncology, Merck sells vaccines, hospital acute-care products and treatments for cardiometabolic and infectious diseases, while its animal health division adds a diversified earnings stream across livestock and companion animals. MarketBeat company overview
The product behind the stock
Keytruda, an immuno-oncology therapy for multiple cancer indications, is Merck’s flagship drug and the single largest contributor to group revenue. The medicine is approved in numerous markets worldwide and has become a central driver of the company’s cash flow.
Where the stock trades today
The shares of Merck & Co. (US58933Y1055) trade on the New York Stock Exchange at $114.04 as of 06/18/2026, 15:59 Eastern Time.
Key facts on Merck & Co. stock
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- WKN: A3DCV6
- Ticker: MRK
- Venue: NYSE
- Price (as of 06/18/2026, 15:59 Eastern Time): 114.04 USD
- Market cap: 281.65 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Standard & Poor's 500 index
- Next earnings date: 07/28/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
